SK pharmteco Focusing On BAU Amid BIO 'Buzz', BIOSECURE

Planned Act Already Prompting CDMO Shifts?

 
• By Jung Won Shin
Joerg Ahlgrimm, CEO of SK pharmteco
SK pharmteco CEO Joerg Ahlgrimm (left) at BIO 2024 • Source: SK pharmteco

More from South Korea

More from Focus On Asia